All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 10, 2020
Details:
Ocumension's IPO marks a significant milestone in its journey to become China's leading ophthalmology platform. Company intent to use these funds to continue expanding its portfolio with innovative new drug assets.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
